Adamis Pharmaceuticals Corp (NASDAQ:ADMP)’s share price rose 18.8% during trading on Wednesday . The company traded as high as $5.05 and last traded at $4.75. Approximately 2,331,800 shares changed hands during mid-day trading, an increase of 216% from the average daily volume of 737,005 shares. The stock had previously closed at $4.00.
ADMP has been the topic of a number of research reports. B. Riley restated a “buy” rating and issued a $9.50 price objective on shares of Adamis Pharmaceuticals in a report on Wednesday, October 4th. Zacks Investment Research downgraded Adamis Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Monday, November 20th. ValuEngine downgraded Adamis Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Tuesday, October 3rd. Maxim Group reiterated a “buy” rating and set a $13.00 target price on shares of Adamis Pharmaceuticals in a report on Monday, August 21st. Finally, Raymond James Financial assumed coverage on Adamis Pharmaceuticals in a report on Tuesday, September 12th. They set an “outperform” rating and a $7.00 target price on the stock. Two analysts have rated the stock with a sell rating and three have assigned a buy rating to the company. Adamis Pharmaceuticals has a consensus rating of “Hold” and an average price target of $10.33.
The company has a debt-to-equity ratio of 0.06, a quick ratio of 3.79 and a current ratio of 3.93.
ILLEGAL ACTIVITY NOTICE: This report was first published by Community Financial News and is owned by of Community Financial News. If you are viewing this report on another website, it was illegally stolen and republished in violation of U.S. and international copyright and trademark laws. The legal version of this report can be accessed at https://www.com-unik.info/2017/12/06/adamis-pharmaceuticals-admp-stock-price-up-18-8.html.
Adamis Pharmaceuticals Company Profile
Adamis Pharmaceuticals Corporation is a pharmaceutical company. The Company is engaged in the development of its specialty pharmaceutical products. The Company is developing various products in the allergy and respiratory markets, including a dry powder inhaler technology that it acquired from 3M Company (3M).
What are top analysts saying about Adamis Pharmaceuticals Corp? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Adamis Pharmaceuticals Corp and related companies.